Development of a standardized real time PCR for Torque teno viruses (TTV) viral load detection and quantification: A new tool for immune monitoring

• Published in: Journal of clinical virology Vol. 105; pp. 118 - 127
• Main Authors: Kulifaj, Dorian, Durgueil-Lariviere, Bénédicte, Meynier, Faustine, Munteanu, Eliza, Pichon, Nicolas, Dubé, Manon, Joannes, Martine, Essig, Marie, Hantz, Sébastien, Barranger, Côme, Alain, Sophie
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.08.2018
• Subjects: Immunosuppression; PCR assay; Torque teno virus; Viral load; PCR assay; Torque teno virus; Immunosuppression; Viral load
• ISSN: 1386-6532; 1873-5967
• DOI: 10.1016/j.jcv.2018.06.010

•Torque teno viruses are small DNA viruses that infect the human being with a high prevalence.•Clinical assays are necessary to further characterize their potential as immunosuppression markers.•This paper presents the first standardized assay for human Torque teno virus viral load quantification in blood and plasma.•With this assay, early kinetics in kidney recipients are close to that previously described in lung transplant recipients. Torque teno viruses (TTV) are small DNA viruses whose replication is closely linked to immune status. A growing number of publications underlined the potential of TTV viral load as an indicator of immunosuppression. To demonstrate the analytical performance of the first standardized RUO (Research Use Only) assay to detect and quantify human TTV DNA in whole blood and plasma. We established analytical performances for TTV load measurement in various populations. The TTV kinetics were followed in kidney recipients. TTV viral load was analyzed on whole blood samples from 42 kidney recipients follow-up, 53 kidney deceased donors and 31 healthy volunteers. The qPCR TTV assay detects the most prevalent human TTV genotypes and does not cross react with other viruses. Limit of detection was 2.2 log10 copies/mL in whole blood and plasma, linearity and precision were demonstrated over the range 1.61 to 10.61 log10 copies/mL in whole blood. Prevalence of TTV DNA in blood differed significantly among groups: 45% in healthy volunteers, 74% in donors and 83% in kidney recipients. In kidney recipients, early TTV kinetics were comparable to those previously observed with in-house assays in other transplant settings: viral load increased from an average of 4.3 log10 to 7.9 log10 copies/mL within the first 75 days post transplantation. This TTV assay showed high analytical sensitivity, specificity, linearity and precision. It is a useful standardized tool to further evaluate TTV load as a biomarker of immune status that could improve individual treatment strategy.